Skip to main content
STTK
NASDAQ Life Sciences

Shattuck Labs Reports Q1 2026 Financials, Reaffirms Cash Runway into 2029, and Advances Clinical Pipeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.48
Mkt Cap
$504.886M
52W Low
$0.712
52W High
$8.33
52W Position info
810% above low
Off High info
22% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

STTK has more than doubled off its 52-week low of $0.712.

Summary

Shattuck Labs reported a Q1 2026 net loss of $14.8 million but reaffirmed its cash runway into 2029, while also announcing the completion of Phase 1 enrollment for SL-325 and plans for a Phase 2 trial.


Key Events · Earnings and Guidance · STTK

  • Q1 2026 Financial Results

    Shattuck Labs reported a net loss of $14.8 million, or $0.13 per basic and diluted share, for the first quarter ended March 31, 2026, compared to a net loss of $13.7 million, or $0.27 per share, for the same period in 2025.

  • Cash Runway Reaffirmed

    The company reported $90.4 million in cash and cash equivalents and investments as of March 31, 2026, and expects this to fund operations into 2029, assuming the full exercise of outstanding common stock warrants.

  • SL-325 Clinical Trial Progress

    Enrollment for all cohorts in the Phase 1 clinical trial of SL-325 is complete, with data expected in the second quarter of 2026. Subject to positive Phase 1 data, a Phase 2 clinical trial in Crohn's disease is expected to initiate in the third quarter of 2026.

  • Bispecific Antibody Development

    Shattuck's lead bispecific antibody has entered IND-enabling activities, with plans to disclose targets, preclinical data, and development timelines in the second quarter of 2026.


Analysis · STTK · Life Sciences

Shattuck Labs, a clinical-stage biotechnology company, reported a widened net loss for Q1 2026, but significantly, reaffirmed its cash runway into 2029, providing crucial financial stability for its ongoing clinical programs. The completion of Phase 1 enrollment for its lead candidate, SL-325, and the planned initiation of a Phase 2 trial in Crohn's disease are key milestones. Additionally, the advancement of a lead bispecific antibody into IND-enabling activities signals continued pipeline development. These clinical advancements, coupled with a strong cash position, are critical for investor confidence in a biotech company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STTK was trading at $6.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.9M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STTK - Latest Insights

STTK
Nov 05, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.47 info
Change: -$1.03 (-19%) info
Market Cap: $454.218M info
STTK
Nov 05, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.47 info
Change: -$1.03 (-19%) info
Market Cap: $454.218M info
STTK
Oct 01, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.79
Real-time Price: $4.47 info
Change: -$2.32 (-34%) info
Market Cap: $454.218M info
STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.47 info
Change: -$2.53 (-36%) info
Market Cap: $454.218M info
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.47 info
Change: -$2.53 (-36%) info
Market Cap: $454.218M info